PSNL Personalis Inc

2,028

$1.53

$0.03

(2.00%)

Today

Watchers	2,028
52-Wk Low	$0.8906
52-Wk High	$4.31

Market Cap	$73.55M
Volume (M)	14.00
52-Wk High	$4.31
52-Wk Low	$0.8906

Fundamentals

Personalis to issue 9.2M shares as Tempus joins hands for cancer testSeekingAlpha.com: All News • 2 days ago

Personalis to issue 9.2M shares as Tempus joins hands for cancer test...

Share to Feed

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer TestingBusiness Wire • 3 days ago

Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic...

LPL Financial LLC Grows Position in Personalis, Inc. (NASDAQ:PSNL)Zolmax • 4 days ago

LPL Financial LLC increased its position in Personalis, Inc. (NASDAQ:PSNL Free Report) by 9.4% in the second quarter, according to the company in its most recent filing with the Securities...

Video: Monday's ETF Movers: ARKG, MOOMarket News Video • 11 days ago

In trading on Monday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 3.3% on the day. Components of that ETF showing particular strength include shares of Personalis, up about...

Myriad Genetics and Personalis Partner to Market Solutions to Pharma CustomersGlobe Newswire • 15 days ago

Myriad expands pharma service offering by introducing Personalis' ImmunoID NeXT platform to its pharmaceutical partners who use MyRisk Hereditary Cancer Test, BRACAnalysis CDx and/or MyChoice CDx...

Personalis Reports Third Quarter 2023 Financial ResultsBusiness Wire • 24 days ago

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business...

Personalis Launches NeXT Personal Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in CancerBusiness Wire • about 1 month ago

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole...

Personalis to Announce Third Quarter 2023 Financial ResultsBusiness Wire • about 1 month ago

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In...

Personalis presents initial findings from work with RACERx lung cancer studyThe Fly • about 1 month ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD TechnologyBusiness Wire • about 1 month ago

Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a...